Cargando...
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Immune checkpoint inhibitors such as ipilimumab, a cytotoxic T-lymphocyte-associated antigen-4 inhibitor, have been widely used for advanced malignancies. As these inhibitors improve antitumor immunity via T-cell modulation, immune-mediated adverse events associated with T-cell activation, such as c...
Gardado en:
| Publicado en: | Case Rep Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
S. Karger AG
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6120399/ https://ncbi.nlm.nih.gov/pubmed/30186138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000491862 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|